Both in Pharmaceuticals
Arcus Biosciences vs NewAmsterdam Pharma Company N.V
Over the past year RCUS returned −7.8% and NAMS returned −47.1%; their daily moves had a correlation of 0.24.
RCUS −7.8% NAMS −47.1%Growth of $1, one year, split-adjusted
| Metric | RCUS | NAMS |
|---|---|---|
| Price | $18.19 | $20.06 |
| Market cap | $2.32B | $2.40B |
| Today | −2.26% | −3.37% |
| 1 month | −27.9% | −17.0% |
| 6 months | −29.2% | −29.4% |
| Year to date | −23.7% | −42.8% |
| 1 year | −10.3% | −44.0% |
| Revenue growth (YoY) | −74.4% | −80.7% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −222.0% | −1732.9% |
| P/E (TTM) | — | — |
| Price / sales | 19.8× | 336.7× |
| Net cash | $601.0M | $633.9M |
| Dividend yield | — | — |
| Volatility (60d) | 62.7% | 50.9% |
| Short % of float | 13.6% | 16.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).